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ABSTRACT
Introduction: Paraneoplastic neurological syn-
dromes (PNS) consist of a heterogeneous group
of neurological disorders triggered by cancer.
The aim of this systematic review is to estimate
the reported prevalence of pain in patients with
paraneoplastic peripheral neuropathy (PPN).
Methods: A systematic computer-based litera-
ture search was conducted on PubMed database.
Results: Our search strategy resulted in the
identification of 126 articles. After the eligibility
assessment, 45 papers met the inclusion criteria.
Full clinical and neurophysiological data were
further extracted and involved 92 patients with
PPN (54.5% males, mean age 60.0 ± 12.2 years).
The commonest first manifestation of PPN is
sensory loss (67.4%), followed by pain (41.3%),
weakness (22.8%), and sensory ataxia (20.7%).
In 13.0% of the cases, pain was the sole first
manifestation of the PPN. During the course of
the PPN, 57.6% of the patients may experience
pain secondary to the neuropathy.
Conclusions: Pain is very prevalent within PPN.
Pain specialists should be aware of this. Detailed
history-taking, full clinical examination, and
requesting nerve conduction studies might lead
to an earlier diagnosis of an underlying
malignancy.
Keywords: Cancer; Pain; Paraneoplastic;
Polyneuropathy
INTRODUCTION
Paraneoplastic neurological syndromes (PNS)
consist of a heterogeneous group of neurologi-
cal disorders triggered by cancer. These syn-
dromes are caused by mechanisms other than
metastases, metabolic or nutritional deficits,
infections, coagulopathy, or side effects of can-
cer treatment such as chemotherapy. The dis-
covery that many PNS are associated with
antibodies against neural antigens expressed by
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the tumor (antineural antibodies) has suggested
that PNS are immune-mediated [1].
The recommended diagnostic criteria for
PNS [2] suggest that the cancer has to develop
within 5 years of the diagnosis of the neuro-
logical disorder. This time period has been
based on reports showing that in the majority of
cases the interval between the PNS and the
diagnosis of cancer is less than 5 years.
Paraneoplastic peripheral neuropathy (PPN)
is one of the commonest PNS reported. The aim
of this paper is to systematically review the
presenting manifestations of patients with PPN
and establish the reported prevalence of pain.
This article follows on from the editorial intro-
duction ‘‘Painful Peripheral Neuropathy and
Cancer’’ (doi:10.1007/s40122-017-0077-2).
METHODS
Literature Search Strategy
Asystematiccomputer-based literature searchwas
conducted on April 6th, 2017 on PubMed data-
base. For the search,weused threeMedical Subject
Headings (MeSH) terms. Term A was ‘‘neu-
ronopathy’’ or ‘‘ganglionopathy’’ or ‘‘neuropa-
thy’’, term Bwas ‘‘paraneoplastic’’ and termCwas
‘‘first manifestation’’ or ‘‘first symptom’’ or ‘‘initial
symptom’’ or ‘‘first manifestations’’ or ‘‘first
symptoms’’ or ‘‘initial symptoms’’ or ‘‘presenting
symptom’’ or ‘‘presenting symptoms’’ or ‘‘pain’’ or
‘‘painful’’. Limitations included language to be
English and full text to be available. We also per-
used the reference lists of the papers in order to
findpapersnot foundthroughthe search strategy.
Inclusion and Exclusion Criteria
To be included in the review, the articles had to
meet the following criteria:
(1) To involve single cases or cases series with
PPN.
(2) To study human adult subjects.
The following exclusion criteria were applied:
(1) Book chapters, reviews, letters to the editor
and editorials that did not provide new
data.
(2) Papers referring only to autonomic
neuropathy.
(3) Papers referring only to cranial
neuropathies.
(4) Papers referring only to small fiber
neuropathies.
(5) Papers referring to POEMS (Polyneuropa-
thy, organomegaly, endocrinopathy, M--
protein and skin changes) syndrome.
(6) Papers referring to motor neuron disease.
(7) Papers providing incomplete clinical or
neurophysiological data about the single
cases/case series.
Data Extraction
Data were extracted from each study in a
structured coding scene using Microsoft Excel
and included information on the article iden-
tification, year of publication, evaluation per-
iod, total number of subjects, gender, age, first
manifestation of the PPN, presence of pain
secondary to the neuropathy, neurophysiologi-
cal type of neuropathy, course of symptoms,
type of cancer, and presence of anti-neuronal
antibodies.
We used the International Association for
the Study of Pain (IASP) definitions to classify
pain as neuropathic or not.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Statistical Analyses
A database was developed using the IBM SPSS
Statistics (version 23.0 for Mac). Frequencies
and descriptive statistics were examined for
each variable. The primary outcomes of inter-
est were the proportion of patients who expe-
rienced pain as a first manifestation of the PPN
and the proportion of patients who experi-
enced pain during their PNS. Further compar-
isons between groups were made using
Student’s t test for continuous data and Chi-
square test for categorical data. A value of
P\0.05 was considered to be statistically
significant.
Pain Ther
RESULTS
Search Results
This search strategy resulted in the identifica-
tion of 126 articles. After the eligibility assess-
ment, 81 articles were excluded. In total, 45
papers met the inclusion criteria and were used
for this review [3–47]. These studies were pub-
lished between 1984 and 2017. Figure 1 illus-
trates the study selection process.
Full clinical and neurophysiological data
were further extracted from 42 papers and
involved 92 patients with PPN (54.5% males).
The age of the patients ranged from 18 to
81 years (mean 60.0 ± 12.2 years). The demo-
graphic and clinical characteristics of these
patients are summarized in Table 1.
Epidemiological Characteristics of PPN
Although PPN is said to be the commonest PNS
(34.9%), followed by encephalomyelitis (23.8%)
and cerebellar degeneration (20.6%) [45], there
is sparse epidemiological data on the prevalence
of neurophysiologically confirmed PPN. The
reasons for this are two-fold. The available
studies to date are either in cohorts of patients
with known malignancy and neuropathic
symptoms or in patients who are seropositive
for well-characterized paraneoplastic antibod-
ies. A correct prevalence study of PPN should
include a large cohort of patients with newly
diagnosed malignancy all of whom should be
evaluated for the presence of PN with nerve
conduction studies, even in the absence of
neuropathic symptoms and paraneoplastic
antibodies.
Fig. 1 PRISMA chart
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Lucchinetti et al. [47] estimated that out of
162 patients seropositive for anti-Hu antibodies
(anti-neuronal antibodies usually associated to
small-cell lung carcinoma), 72.8% presented
with neuropathic symptoms. Most commonly,
the patients presented with pure sensory
(40.1%), followed by mixed sensory and motor
(30.2%) and pure motor symptoms (2.4%) [47].
However, no neurophysiological data were
provided in this study.
In another series of 150 patients with a
biopsy confirmed SCLC, Elrington et al. [6]
estimated that the prevalence of sensory symp-
toms was 16% and the prevalence of motor
symptoms 44%. However, a definite neuropathy
was confirmed with nerve conduction studies
only in one patient (0.7% of the total study
population).
Graus et al. [46] presented a series of 200
patients, seropositive for anti-Hu antibodies,
and estimated that 54% were present with pre-
dominantly sensory neuropathy and 4.5% with
sensorimotor neuropathy. However, no infor-
mation was given about whether nerve con-
duction studies were done in all patients, and
what type of neuropathy these patients pre-
sented with.
Clinical Manifestations of PPN
The commonest early manifestation of PPN is
sensory loss (67.4%), followed by pain (41.3%),
weakness (22.8%), and sensory ataxia (20.7%).
Table 1 Descriptive of studies included in the
meta-analysis
Parameter Value
Number of papersa 42
Type of papers
Case report (%) 29 (75.0)
Case series (%) 13 (25.0)
Total number of patients 92
Male:female 3:2
Mean age, in years (SD) 60.0 (12.2)
Presenting manifestations (%)
Ataxia 19 (20.7)
Sensory deﬁcit 62 (67.4)
Pain 38 (41.3)
Weakness 21 (22.8)
Pain at any point (%) 53 (57.6)
Type of pain (%)
Neuropathic 51 (96.2)
Nociceptive 2 (3.8)
Type of neuropathy (%)
Axonal 80 (87.0)
Symmetrical sensorimotor
Symmetrical sensory
Sensory ganglionopathy
Mononeuritis multiplex
Pure motor
21 (22.8)
21 (22.8)
25 (27.2)
6 (6.5)
7 (7.6)
Demyelinating 12 (13.0)
Temporal evolution of neuropathy (%)
Acute 12 (13.0)
Sub-acute 59 (64.1)
Progressive/chronic 21 (22.8)
Type of malignancy (%)
Lung 42 (45.7)
Mediastinal 4 (4.3)
Hematological 15 (16.3)
Table 1 continued
Parameter Value
Gastro-intestinal 11 (12.0)
Gynecological 8 (8.7)
Other 6 (6.5)
Unknown primary 6 (6.5)
Anti-Hu antibodiesb (%) 47 (61.8)
SD standard deviation
a Three more papers provided useful information on
epidemiology and were used in the review, but they did not
provide full clinical data on individual cases
b Tested in 76 patients
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In 39.1% of the cases, the presenting com-
plaints included more than one symptom.
However, in 13.0% of the cases, pain was the
sole first manifestation of the PPN. During the
course of the PPN, 57.6% of the patients repor-
ted pain secondary to the neuropathy. In the
majority of these patients (96.2%), the pain was
directly related to the neuropathy (considered
as neuropathic) as described in the papers
included in this review; however no validated
tools were used to systematically assess and
record other neuropathic symptoms accompa-
nying pain. A minority of patients reported pain
indirectly related to the neuropathy (not neu-
ropathic), secondary to painful muscle cramps.
Temporal Evolution of PPN and Pain
Most reports classified PPN as acute, sub-acute
or chronic/progressive. Acute were those neu-
ropathies that evolved within 1 month, sub--
acute were those that evolved between 1 and
6 months, and chronic the neuropathies that
slowly kept progressing beyond 6 months.
Based on these reports, we estimated that PPN
are sub-acute in the majority of cases (64.1%),
followed by chronic (22.8%) and acute (13.0%).
Neurophysiological Types of PPN and Pain
Large fiber neuropathy can be axonal or
demyelinating. In axonal neuropathy, axons are
affected usually in proportion to their length
(length dependent). In demyelinating neu-
ropathy, the myelin sheath around axons is
affected, and as a result, the ability of the axons
to speedily conduct electrical impulses is
impaired. The latter leads to slow or no con-
duction (conduction block). Sensory neu-
ronopathy, or ganglionopathy, is another large
fiber peripheral neuropathy, in which the cell
bodies of the sensory neurons located in the
dorsal root ganglia are affected. Finally, in pure
motor neuropathy, there is involvement of only
the lower motor neurons [48].
Demyelinating neuropathies were reported
in 13% of PPN cases. Among the axonal PPN
(87%), the most common neurophysiological
type was asymmetrical sensory ganglionopathy
(27.2%), followed by symmetrical sensorimotor
neuropathy (23.9%), symmetrical sensory neu-
ropathy (21.7%), pure motor neuropathy
(7.6%), and mononeuritis multiplex (6.5%).
Figure 2 illustrates how common is pain based
on the neurophysiological type of the PPN.
Though rare, the most painful type of PPN is
mononeuritis multiplex. Mononeuritis multi-
plex is known to occur in many illnesses
including certain types of systemic vasculitis
[49]. Indeed, in the majority of patients with
paraneoplastic mononeuritis multiplex a nerve
biopsy was performed, showing evidence for
vasculitis [36, 39].
Although pure motor neuropathy is the least
common, it can still be painful. The major dif-
ference in the pain reported in such cases is that
it is muscular in nature, most commonly
because of cramps [40].
Paraneoplastic Antibodies and Painful
PPN
Out of 76 patients with painful PPN tested for
anti-Hu antibodies, 47 were positive (61.8%).
Other antibodies that have been associated with
PPN are anti-amphiphysin and anti-CV2 anti-
bodies. Interestingly enough, patients with
anti-Hu antibodies were more likely to present
with pain as a first manifestation compared to
patients without anti-Hu antibodies (53.2 vs.
24.1%, p = 0.013). Also, patients with anti-Hu
antibodies were more likely to present with pain
secondary to the PPN at any point compared to
patients without anti-Hu antibodies (74.5 vs.
41.4%, p = 0.004).
Cancer Types and Painful PPN
Lung cancer was the commonest cause of PPN
(45.7%), followed by hematological malignan-
cies (16.3%) and gastro-intestinal tract malig-
nancies (12.0%). The majority of patients
seropositive for anti-Hu had lung cancer
(66.0%). Detailed data regarding type of malig-
nancy are shown in Table 1. Cancer type was
not related significantly to pain either as a first
manifestation or during the course of the PPN
(p[0.05).
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PPN and Cancer Relapse
PNS can be the first manifestation of cancer
relapse [8, 17, 20] and they often precede the
clinical or radiological diagnosis of a local relapse
or distant metastases. Patients with a history of
cancer presenting with peripheral neuropathic
pain, not otherwise explained, can be diagnosed
with PNS when circulating paraneoplastic anti-
bodies are detected or a PET scan is positive.
Management
Management of pain as a result of paraneoplastic
neuropathy does not differ from the published
guidelines on the management of neuropathic
pain [50]. However, it is commonly reported that
treatment for the underlying malignancy (in-
cluding tumor resection and/or chemotherapy)
can improve the symptoms [3, 11, 28, 30, 37].
CONCLUSIONS
This systematic review and meta-analysis indi-
cates the following key points:
(1) Pure sensory neuropathy (sensory gan-
glionopathies and symmetrical sensory
neuropathies) is the commonest form of
PPN reported. A full neurophysiological
assessment is therefore advisable in all
suspected cases. Such a finding may
prompt searching for an underlying
malignancy.
(2) The commonest first manifestation of PPN
is sensory loss (67.4%), followed by pain
(41.3%), weakness (22.8%), and sensory
ataxia (20.7%).
(3) Pain is prevalent in PPN, as almost three
out of five patients with PPN will experi-
ence peripheral neuropathic pain at some
point in the course of the PNS. The major-
ity of the patients will experience neuro-
pathic pain, but patients with pure motor
neuropathies also experience pain sec-
ondary to cramps.
(4) One out of seven patients with PPN will
experience pain as the sole manifestation.
Therefore, pain specialists should be aware
that they may be the first to encounter
patients whose pain may be a paraneoplas-
tic phenomenon. Therefore, detailed
Fig. 2 Pain as a symptom among the different neuro-
physiological types of paraneoplastic peripheral neu-
ropathies given in percentages. SG sensory
ganglionopathy, SMA sensorimotor axonal neuropathy,
SN symmetrical sensory neuropathy, PM pure motor
neuropathy, MMX mononeuritis multiplex
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history taking, full clinical examination,
and neurophysiological assessment—espe-
cially of sub-acute onset and of unknown
etiology—may lead to an earlier diagnosis
of an underlying malignancy.
(5) Testing for paraneoplastic antibodies (i.e.,
anti-Hu and anti-CV2), especially in sen-
sory neuropathies that evolve sub-acutely,
might also be helpful in earlier diagnosis of
a PPN.
(6) PNS can occur as part of cancer relapse and
pain can be the first manifestation in such
cases. Therefore, patients with a past his-
tory of malignancy who present with neu-
ropathic symptoms, including pain and
have evidence of a PN on neurophysiology
should be investigated further for a possi-
ble relapse. A PET scan might be useful in
the earlier diagnosis of PNS [27].
(7) Among the papers included in this review,
different terms have been used to describe
the presenting symptoms. The use of val-
idated tools [51] for assessing the presence
of pain and the quality of the related
characteristics might be useful for future
prospective studies.
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